Möchten Sie immer auf dem neuesten Stand bleiben?

Achieved complete target inhibition, durable tumor control, and a 36-fold dose range without dose-limiting toxicity— advancing toward combination trials.

TRE-515, the only dCK inhibitor in development, secures $1.8M NIH grant after outperforming market-leader Stelara in Crohn’s studies.

Phase 1 enrollment of TRE-515 in solid tumors completed; 36-fold dose escalation well tolerated, with early signs of antitumor activity and durable benefit

Fresh NIH funding follows FDA Fast Track designation, reinforcing confidence in TRE-515 potential to advance prostate cancer treatment.

$3M NIH grant advances TRE-515, a first-in-class lupus therapy. Funding supports safety, biomarker studies, and paves the way for patient trials.

Creates platform for precision dosing, companion diagnostics, streamlined development, and broader use across cancer and autoimmune diseases.

TRE-515 receives FDA Fast Track for use with Pluvicto™ in advanced prostate cancer, aiming to improve outcomes in PSMA-positive, treatment-resistant cases.

Global exclusive agreement expands patent coverage for compound structures and autoimmune uses across major pharmaceutical markets

Trethera enlists leading expert in demyelinating diseases to advance TRE-515, a first-in-class drug with FDA Orphan Drug status for ADEM and optic neuritis

LOS ANGELES, April 22, 2025 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune diseases,...